AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
Background and purpose: More than half of Parkinson’s (PD) disease patients use nutritional supplements and other methods of complementary medicine (CAM). Only a minority discuss their use with their ...
You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.
You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback